SCHEMBL3476567

SCHEMBL3476567

CC(C)(C)OC(=O)CCn1c(=O)c(C(C)(C)C)nc2cc(-c3cccc(C(F)(F)F)c3)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 10/20 0.41
GRIN2B Q13224 10/20 0.41
TGFBR1 P36897 1/20 0.40
PIN1 Q13526 1/20 0.39
LMNA P02545 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
SCD O00767 3/20 0.38
MAPT P10636 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3476237 0.89 PIN1 (0.43) GRIN1GRIN2BTGFBR1PIN1LMNA
SCHEMBL3473446 0.86 TGFBR1 (0.44) GRIN1GRIN2BTGFBR1KDM4ESCD
SCHEMBL3350638 0.81 PIN1 (0.45) GRIN1GRIN2BPIN1SCD
SCHEMBL3474070 0.79 TGFBR1 (0.49) GRIN1GRIN2BTGFBR1LMNAKDM4E
SCHEMBL3433129 0.78 SCD (0.47) GRIN1GRIN2BTGFBR1SCD
SCHEMBL3474113 0.76 EGLN1 (0.41) GRIN1GRIN2BPIN1KDM4EALDH1A1
SCHEMBL3474093 0.76 AKR1C3 (0.43) GRIN1GRIN2BKDM4ESCD
SCHEMBL3473761 0.73 S1PR1 (0.41) PIN1SCD
SCHEMBL3433378 0.72 TGFBR1 (0.51) GRIN1GRIN2BTGFBR1LMNAKDM4E
SCHEMBL3473451 0.72 KMO (0.43) GRIN1GRIN2BPIN1SCDJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912190-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-12-16 US claimed
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-08-01 US claimed
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8912190-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-12-16 US disclosed
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-08-01 US disclosed
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, KCNJ2, KCNH2 GRIN1 1435/4885GRIN2B 2067/4885TGFBR1 1618/4885
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, KCNJ2, KCNH2 GRIN1 1435/4885GRIN2B 2067/4885TGFBR1 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.